Novo Nordisk A S annual ebitda
2022
2023
2024
2025
Novo Nordisk A S EBITDA Growth & History (NVO)
Novo Nordisk A S's calculated EBITDA was kr142.32B for fiscal 2025.
View full Novo Nordisk A S company overviewNovo Nordisk A S annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | kr142.32B | kr5.44B | +3.97% |
| 2024 | 2024-12-31 | kr136.88B | kr27.02B | +24.60% |
| 2023 | 2023-12-31 | kr109.86B | kr28.50B | +35.03% |
| 2022 | 2022-12-31 | kr81.36B | — | — |
Novo Nordisk A S quarterly ebitda
No reported data
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|
Novo Nordisk A S ebitda trends
Across the available reported history, Novo Nordisk A S's ebitda increased from kr136.88B to kr142.32B, a change of kr5.44B.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novo Nordisk A S filings at SEC.gov ↗